Biotechnology Market Research Reports & Industry Analysis

The collection includes the following reports: Charting the Biosimilar and Biobetter Development Pipeline (2013) Biosimilar Defensive Plays - assessing the options Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets (Volume 1 and Volume 2)

... emerging market experience in India and Mexico. Rituximab biosililar pipeline, and the current status of clinical development What are the Innovator's strategy in protecting rituximab franchise? Competition to biosimilar rituximab ...

... of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

... Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, ... parameters for each drug profile in development phase are covered in “Global Cell Therapy Pipeline Analysis” research report: Drug Profile Overview ...

... the development of biological drugs in the next few years. In recent years, China bio-pharmaceuticals industry develops rapidly, but antibody drugs lag ... products in the future. Monoclonal antibody still belongs to high-end products in China market, which mainly depends on import. In 2012, the market scale ...

... , losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the ... ) comes in. Scope Charting the Biosimilar and Biobetter Development Pipeline (2013) will help you to: Understand the landscape of biosimilar/biobetter development ...

... . This insightful report brings you completely up to date with the biosimilar competitive landscape, and gives you the information you need ... .” Warwick Smith, director-general, British Generic Manufacturers Association Biosimilar Defensive Plays - assessing the options is designed to answer your strategic and ...

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated ...

... in the stem cell banking market of India. “India Stem Cell Banking Market Analysis” research report outlines following aspects related to booming stem cell banking in India: India Stem Cell Research & Therapy Market Overview Stem Cell Banking Market Overview Cord Blood & Menstrual Banking Cost Analysis ...

The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roche’s/Biogen Idec’s Rituxan/MabThera (rituximab), Merck ...

... forces as compared to generics, a number of companies aim to exploit this – Japan has seen a flood like consolidation and partnering activities in biosimilar ... , Yoshindo etc. to be amongst the key players in biogenerics business in Japan. In this piece, we attempt to evaluate the future competitive landscape of ...

... rates of stem cell banking ranging from 15% to 30%. Regions such as, US, Europe, China and India have low penetration ... stem cells from embryos. The report titled ‘Indian Stem Cell Banking Market: Trend and Opportunities (2012-2017)’ provides an in-depth analysis of the Indian stem cell banking market ...

... next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and ... diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on: Drug ...

... one third for the global biosimulation market. Europe is the fastest growing market for biosimulation the growth is attributed to the efforts of regulatory bodies in promoting new technologies in drug discovery and development. Asian market ...

... barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential ... their impact on Market Opportunity Global Regulatory Process and Hurdles Risk/Reward profile of developing Herceptin biosimilar

... 4 insulin biosimilars available in the Indian market. The acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched. “India Biosimilar Market Analysis” research report by KuicK research gives detailed insight on various aspects related the biosimilar market in India like Market Overview, Biosimilar Pipeline Analysis, Biosimilar Development Capabilities ...

The report is sent in 0-2 business days after order is placed. The stem cell research in India is in its nascent stage and is gradually on a growth path of acceptance by ... covers the market size and growth prospect of the stem cell banking market in India. In addition to these, the report gives a snapshot of ...

... lower return on investments continues to challenge the attractiveness of the biosimilars market. The report analyzes the global biosimilars market. The various drivers and challenges faced by the ...

The biosimilars industry has been growing stupendously across the globe for the past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivi...

For the past few years, the biosimilars industry has been growing stupendously across the globe due to increasing healthcare costs and rising aging population. It is expected to evolve, to a great ext...

Across the globe, the biosimilars industry has been growing stupendously for the past few years. Increasing healthcare costs and rising aging population are driving the industry that is expected to ev...

Celltrion filed infliximab biosimilar (CT-P13) in Europe and was accepted for review by EMA. It is the first biosimilar mAb to be filed for approval in Europe. The patent ... Celltrion conducted PhI and PhIII clinical trials with the duration of 12 months in more than 850 patients. It has already filed Infliximab ...

Antibody medicine is generally obtained from monoclonal antibody through genetic engineering, possessing the advantages of strong targeting and few drug side effects. At the present time, it is mainly...

The biosimilars industry has been growing stupendously across the globe for past few years. Increasing healthcare costs and rising aging population are driving the industry, which stands at a vivid po...

It was supposed to be the “epoch of biosimilars”, or drugs that copied existing biologics but had the potential to be more cost-effective. Yet five years later, biosimilars have failed to reach their...

... and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and ... , Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary ...

Single User PDF Format: US$ 1,400.00 Multi-User License: US$ 1,800.00 Hard Copy: US$ 1,500.00 CD-ROM: US$ 1,500.00 The global biosimilars industry has been growing stupendously since t...

China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries in terms of industrialization. In 2010, the market...

... Brazil biomaterial market. Plus, the report offers a detailed analysis of the market trends, opportunities, and the factors influencing the growth of each segment of the biomaterials market ...

... biomaterials is expected to reach $64.7 billion in 2015 from $25.6 billion in 2008 with a CAGR of 15% from 2010 to 2015. In 2010, the orthopedic biomaterial market recorded revenues of $12 billion or 37.5% of the total global biomaterial market ... , at a CAGR of 12.7% (2010 to 2015) because the market is relatively mature compared to other product markets. Cardiovascular biomaterial is the second-highest market, and contributed 36.1% to the global biomaterial market in 2010. With the ...

Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,400.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 900.00 The stem cell market has been growing at a fast pace for the past few yea...

From Canada and the US to Japan, the EU and Australia, regulators around the world are establishing guidelines that will pave the way for competition between biosimilars and costly biologics. For many...

They’re costly to develop, fraught with potential patient safety concerns and subject to regulations that have yet to be written. Yet for the pharmaceutical industry, biosimilar monoclonal antibodies...

This report analyzes the US Market for Stem Cells Research in US$ Million. Annual forecasts are provided for the period 2006 through 2015. The ... , Inc., Osiris Therapeutics, StemCells, Inc., ThermoGenesis Corp., and ViaCord, LLC. Market data and analytics are derived from primary and secondary research. ...

... previously been no effective treatment. The medical stem cells market is divided into three categories: stem cell therapeutics, cord blood banking and drug ... projected to be the second largest and second fastest growing market. US is the major stem cell market in the world and has recently been boosted by ...

Product description The present Competitive Intelligence Report about Antibody Therapy of Inflammatory and Autoimmune Diseases provides a competitor evaluation in the field of antibody therapeutics used or being developed for treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, ulcerative colitis ...

Single User PDF Format: US$ 1,200.00 Multi-User License: US$ 1,600.00 Hard Copy: US$ 1,300.00 CD-ROM: US$ 1,300.00 Considered as an indispensable tool in the clinical and biotechnology...

The report “Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers” provides a description and ... range of possibilities, the selection of the most robust and adequate technologies fitting fitting to the product target profile has become more ...

... numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the Antibody Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase. ...

Product description The present Competitive Intelligence Report about Biosimilar and Biobetter/Biosuperior Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyc...

Worldwide, the story is the same. Governments want cheaper drugs for their populations, while the number and kinds of diseases affecting them continue to evolve and grow. Since 1976, when Genentech be...

Embryonic stem cell (hESC) research has attracted a lot of attention the world over and the controversy surrounding it just does not seem to die down. Stem cells are unspecialized cells that are capable of differentiating into any other cell type....

This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for US, Europe, and Japan. ... , Shantha Biotechnics Ltd., Teva Pharmaceutical Industries Ltd., and Wockhardt Ltd. Market data and analytics are derived from primary and secondary ...

... the global stem cell market as follows: • Stem Cell Products (adult stem cell, human embryonic stem cell, and other stem cell types) • Stem Cell Services (stem cell banking, stem cell ... and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We ...

... global biomaterial market as follows: Biomaterials product market Orthopaedic, cardiovascular, gastrointestinal, wound care, plastic surgery, urological and others Biomaterials ingredient market Metals, polymers, ceramics, composites Biomaterials application market ...

... numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into ... of the global biosimilars market. The American market is expected to dominate in 2014 after the U.S. market opens up in 2010. Currently, the global biosimilars market is highly ...

Global Biomarker technologies Market to reach USD 96.8 billion by 2025. Global Biomarker technologies Market valued approximately USD 42.8 billion in 2016 is ... Audience of the Global Biomarker technologies Market in Market Study: Key Consulting Companies & Advisors Large, medium-sized, and small enterprises ...